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Abstract
Background: Clot formation is a crucial moment in the patophysiology of acute coronary
syndromes. The aim of this research was to assess the relationship between immunoglobulin E
(IgE), lipid parameters and chosen hemostatic markers. The role of IgE as a possible partici-
pant in the atherothrombotic process was also investigated.
Methods: A total of 80 patients with acute myocardial infarction (MI) was enrolled in the
study. Concentrations of IgE, plasma lipid parameters, lipoprotein(a), markers of thrombin
generation (TAT, AT III), markers of fibrinolysis (tPA:Ag, PAI-1:Ag, PAP, D-dimers) and
markers of endothelial damage (von Willebrand factor) were measured in blood samples
collected immediately after admission, before any treatment administration.
Results: In patients with acute MI and with IgE concentration above 100 kU/l, IgE values
were strongly, positively correlated with LDL concentration (p < 0.05), lipoprotein(a) concen-
tration (p < 0.02) and negatively correlated with HDL plasma levels (p < 0.02). Exclusion of
patients with IgE concentration lower than 150 kU/l strengthened the correlation between IgE
concentration and LDL (p < 0.002) and lipoprotein(a) (p < 0.01) levels. It also revealed
a significant correlation between IgE and TAT (p < 0.001), IgE and AT III (p < 0.002), and
IgE and D-dimers (p < 0.05). IgE and TAT values measured 7, 14 and 40 days after
infarction also showed significant positive correlation between increments of these parameters.
Conclusions: In patients with acute MI, a significant increase of thrombinogenesis and
fibrinolysis markers is observed. Positive correlation between IgE concentration above 100 kU/l
and markers of thrombinogenesis activation, lipid parameters and lipoprotein(a) levels, with
significance increasing with IgE concentration and constant positive correlation between
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increments of IgE and TAT, can serve as evidence of IgE participation in the atherothrombotic
process. (Cardiol J 2007; 14: 266273)
Key words: myocardial infarction, markers of thrombinogenesis and fibrinolysis,
immunoglobulin E
Introduction
In clinical practice, we very often observe
people with ischemic heart disease (IHD) with no
generally known predisposing risk factors diag-
nosed, which confirms that the variety of causes of
acute coronary syndromes is still not fully ex-
plained. The role of immunity mechanisms in the
development of atherosclerosis and its thrombotic
complications has been recognised and appreciat-
ed [13] in the last 20 years. In the blood circula-
tion of patients with atherosclerosis, antibodies
against oxidised LDL have been detected, as well
as circulating immunity complexes consisting of
LDL and antibodies against them [4]. In some my-
ocardial infarction (MI) patients, high concentra-
tions of antibodies against chlamydia pneumoniae
have been found, which suggests that atheroscle-
rosis and its thrombotic complications may have an
infectious etiology [5, 6].
Recently, attention has been drawn to in-
creased serum immunoglobulin E (IgE) concentra-
tions in patients with cardiovascular diseases, and
myocardial infarction in particular [710]. It is as-
sumed that there exist many relations between IgE
concentrations and antigen-activated mast cells, and
the progression of atheromatic changes and throm-
botic complications. It has therefore been stated
that local antigen stimulation of mast cells, on the
surface of which IgE is found, may lead to foam cell
formation within arterial walls [11, 12]. The activa-
tion of mast cells with the use of physiological
stimulants, such as IgE, C3 and C5, causes the
discharge of mediators such as histamines, heparin
and neutral proteases [12]. However, it was con-
cluded that mast cells might also be activated to
degranulation without IgE, for instance by means
of complement, lymphocytes T and macrophages [13].
The fact that mast cells are present in atheromatic
lesions beside activated lymphocytes T, comple-
ment components, macrophages and cytokines,
proves that mastocytes are among the main cells
in atherogenesis [2, 14]. It was observed that the
progress of atheromatic changes in coronary arter-
ies is connected with a greater number of mast cells
in adventitia of coronary vessels that are also
present between myocytes and in the arterial inti-
ma. Disruption of atheromatic plaque leads to ad-
hesion and aggregation of platelets, as well as to
thrombin activation and fibrin formation. A disturbed
hemostatic balance is evident mainly in the activa-
tion of coagulation cascade, a clinical consequence
of which may be the partial or full closure of a vessel
with symptoms of unstable angina pectoris, myocar-
dial infarction or sudden cardiac death [15].
In the last decade, the list of markers enabling
the detection of thrombotic risk [16] has widened.
The most important are thrombin-antithrombin III
complexes (TAT); they reflect the intensity of
thrombinogenesis in vivo and belong to the most sen-
sitive and most specific markers of thrombosis [17].
Among factors crucial for the development of IHD
are: fibrinogen, factor VII, von Willebrand factor
(vWF), tissue plasminogen activator (t-PA), plas-
minogen activator inhibitor type 1 (PAI-1) and
lipoprotein(a) [Lp(a)]. Some of them (vWF, t-PA, Lp(a)
and fibrinogen) were described as independent bio-
logical risk factors, on the basis of which the occur-
rence of coronary episodes may be predicted [18].
The key enzyme, which is formed during the
activation of fibrinolysis, is plasmin. The test eval-
uating the amount of the forming plasmin is the
determination of plasmin-a2-antiplasmin (PAP) con-
centration. PAP complex determination is a rela-
tively new method of examining the fibrinolytic
system, and their increased concentration serves
as evidence of intensified plasminogenesis in vivo.
Plasmin acting on the fibrin net results in the for-
mation of various size fragments, the smallest of
which are D-dimers (DD). Increased concentrations
of DD are evidence not only of the activated coagu-
lation system, but also of active fibrinolysis [19].
Bearing in mind the significance of the prob-
lem of coronary heart disease in developed coun-
tries, as well as its scientific and practical aspects,
the study has been undertaken to explain whether
and what relation there is between IgE and coagu-
lation and fibrinolysis markers, endothelium dam-
age and lipid parameters, in patients with acute
myocardial infarction. Furthermore, it has been
checked if the relation is dependent on concentra-
tions of the evaluated parameters.
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Methods
The study included 80 STEMI patients, with-
out cardiac arrest or cardiogenic shock before ad-
mission to hospital, without any concomitant chron-
ic inflammatory diseases and without personal or
family history of allergy, aged 3770 (average age
55; 52 males), and 39 healthy persons (average age
52.5; 28 males). Myocardial infarction was diag-
nosed on the basis of typical anamnesis, typical
changes in serial ECGs and laboratory tests con-
firming cardiomyocytes necrosis, i.e. troponin I and
the fraction of creatine phosphokinase (CK-MB).
Blood for examination was sampled immediate-
ly after admission to hospital and obtaining the pa-
tients written consent and before standard treat-
ment administration. Fasting blood samples were
taken from the control group in the morning (be-
tween 7 and 9 a.m.), after 30 minutes rest, in su-
pine position; the venopuncture was done in the
antecubital region with no venostasis.
TAT complex concentrations were measured
with a Enzygnost TAT kit manufactured by Behring-
Marburg (ELISA) (normal range 1.04.1 mg/l). Bio-
logical activity of antithrombin III in serum was
determined with the use of chromogenic substrate
and spectrophotometry with the Berichrom Anti-
thrombin III test by Boehringer Mannheim (normal
values: 80120%). Tissue plasminogen activator
antigen (t-PA:Ag) was examined by means of the
Imulysefi t-PA test by Biopool (normal range: 3
10 ng/ml). The concentration of tissue type plas-
minogen activator inhibitor type 1 (PAI-1:Ag) was
determined by the Imulysefi PAI-1 test  by Biopool
(normal range 443 ng/ml). The concentration of
plasmin-a2-antyplasmin (PAP) complexes was
measured using Enzygnost PAP test by Behring
Marburg (normal range: 120700 ng/ml). The con-
centration of D-dimers was determined by means
of VIDA kit by BioMeriØux, using the immunoen-
zymatic method with fluorescent readout (normal
range: 70500 ng/ml). The concentration of von
Willebrandt factor was determined using the
Asserachromfi vWF test by Diagnostica Stago-
-Boehringer Mannheim (normal values 50160%).
The fibrinogen concentration was measured by
means of the colorimetric method using Hemola
fibrinomat test by Biomerieux (normal range 2.0
4.0 g/l). Lp(a) was determined by an immunoen-
zymatic ELISA method using a CORMAY kit (nor-
mal values up to 30 mg%). Serum IgE was meas-
ured using the Pharmacia Uni-cap Total IgE kit by
FEIA technique, on an automatic analyser Unicap
100, in accordance with the WHO 75/502 standard.
In all patients we evaluated concentrations of
total cholesterol, LDL and HDL cholesterol frac-
tions and triglycerids, using the enzymatic test
manufactured by Biomerieux.
The time elapsing from the onset of pain until
admission to hospital did not exceed six hours, on
average. Statistical analysis was performed with the
use of Statistica 5.0 for Windows 95 by StatSoftfi.
Local research Ethical Committee at the Medical
University in Bydgoszcz gave its consent to the
study.
Results
The comparison of baseline lipid parameters
and markers of coagulation, fibrinolysis and endothe-
lium damage in MI patients and in the control group
revealed highly significant differences; mean concen-
trations of TAT, PAI-1:Ag, PAP and t-PA:Ag consid-
erably exceeded norms in the MI group (Table 1, 2).
The correlation of IgE concentrations with the
concentrations of selected markers of coagulation,
fibrinolysis and endothelium damage in MI patients,
regardless of the level of IgE concentration, did not
reveal any statistical significance apart from a neg-
ative correlation with PAP.
The correlation of log (IgE) with the evaluated
parameters in MI patients with IgE concentration
above 100 kU/L revealed a statistically significant
correlation with LDL (p < 0.05) and Lp(a) (p < 0.02)
and a negative correlation with HDL (p < 0.02).
Also, a positive correlation was observed with to-
tal cholesterol, TAT and AT III but with no statis-
tical significance (Table 3).
The exclusion of patients with IgE concentra-
tions below 150 kU/L strengthened the correlation
Table 1. Comparison of lipid parameters in myocardial infarction patients (MI group, n = 80) and in
control group (n = 39).
CH [mg/dl] HDL [mg/dl] LDL [mg/dl] TG [mg/dl] Lp(a) [mg/dl]
MI group 233.70 – 47.67 47.81 – 13.94 155.67 – 41.09 147.95 – 64.45 49.81 – 32.35
Control group 201.64 – 28.67 50.05 – 11.15 129.32 – 27.63 115.61 – 47.40 30.63 – 22.93
p 0.001 NS 0.001 0.001 0.01
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with the total cholesterol level and a negative one
with HDL (Table 4).
Further exclusion of patients with IgE concen-
trations below 200 kU/L revealed a maintained pos-
itive correlation of increased concentrations of
Table 2. Comparison of baseline hemostatic parameters in myocardial infarction patients (n = 80) and
in control group (n = 39).
Parameter (units) Myocardial infarction (x – SD) Control group (x – SD) p
Thrombin generation markers
TAT [mg/l] 23.06 – 33.09 3.41 – 1.76 0.001
Log(TAT) 0.99 – 0.55 0.48 – 0.21 0.001
ATIII [%] 115.16 – 17.34 99.44 – 10.49 0.001
Fibrinolysis system markers
t-PA:Ag [ng/ml] 13.50 – 8.02 7.74 – 2.84 0.001
PAI-1:Ag [ng/ml] 29.14 – 26.26 20.84 – 9.08 0.02
PAP [ng/ml] 947.55 – 805.30 236.04 – 66.41 0.001
D-dimers [ng/ml] 614.09 – 946.01 221.38 – 101.06 0.001
Endothelium damage markers
vWF [%] 144.46 – 32.22 100.58 – 12.91 0.001
t-PA:Ag [ng/ml] 13.50 – 8.02 7.74 – 2.84 0.001
Other selected hemostasis parameters
Platelets [G/L] 233.04 – 57.37 224.05 – 48.82 NS
Fibrinogen [g/l] 3.81 – 1.03 3.04 – 0.54 0.001
APTT [s] 29.75 – 5.01 31.44 – 5.51 NS
INR 0.92 – 0.07 0.91 – 0.06 NS
Table 3. Correlation of log(IgE) with lipid and he-
mostatic parameters in myocardial infarction pa-
tients with baseline IgE level above 100 kU/l.
Covariables Correlation Significance
coefficient (r) level (p)
Lipid parameters
CH [mg/dl] 0.22 NS
HDL [mg/ml] 0.40 0.05
LDL [mg/dl] 0.40 0.05
TG [mg/dl] 0.11 NS
Lp(a) [mg/dl] 0.51 0.02
Thrombin generation markers
TAT [mg/l] 0.29 NS
Log(TAT) [mg/l] 0.20 NS
ATIII [%] 0.21 NS
Fibrinolytic system markers
t-PA:Ag [ng/ml] 0.10 NS
PAI-1:Ag [ng/ml] 0.13 NS
PAP [ng/ml] 0.16 NS
D-dimers [ng/ml] 0.02 NS
Endothelium damage markers
v. Willebrand [%] 0.17 NS
t-PA:Ag [ng/ml] 0.10 NS
Table 4. Correlation of log(IgE) with lipid and
hemostatic parameters in myocardial infarction
patients with baseline IgE level above 150 kU/l.
Covariables Correlation Significance
coefficient (r) level (p)
Lipid parameters
CH [mg/dl] 0.35 NS
HDL [mg/ml] 0.40 NS
LDL [mg/dl] 0.74 0.002
TG [mg/dl] 0.39 NS
Lp(a) [mg/dl] 0.63 0.01
Thrombin generation markers
TAT [mg/l] 0.76 0.001
Log(TAT) [mg/l] 0.68 0.002
ATIII [%] 0.54 0.02
Fibrinolytic system markers
t-PA:Ag [ng/ml] 0.02 NS
PAI-1:Ag [ng/ml] 0.44 NS
PAP [ng/ml] 0.11 NS
D-dimers [ng/ml] 0.44 0.05
Endothelium damage markers
v. Willebrand [%] 0.21 NS
t-PA:Ag [ng/ml] 0.02 NS
of log(IgE) with LDL (p < 0.002) and Lp(a) (p<0.01)
and revealed a strong correlation with TAT (p < 0.001),
ATIII (p < 002) and a weaker but significant corre-
lation with DD (p < 0.05). Still, there existed a pos-
itive and almost statistically significant correlation
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log(IgE) with total cholesterol (p < 0.05) and LDL
(p < 0.02), together with a positive and almost sta-
tistically significant correlation with Lp(a). A strong
correlation with log(TAT) (p < 0.002) and a posi-
tive significant correlation with  AT III (p < 0.05)
was still maintained (Table 5).
The correlation between the positive or nega-
tive increments of values of IgE and simultaneous
increase in concentrations of the thrombinogene-
sis markers, for which the strongest correlation
with IgE was proven, showed that on the 7th, 14th,
and 40th days after the infarction, a positive signifi-
cant correlation of IgE concentration increments
with TAT concentration increase was maintained.
This served as evidence for the previously found
relation between IgE concentration and TAT levels
in MI patients (Table 6).
Discussion
While discussing the role which immunoglobulin
E may play in the atherothrombotic process the result
of which is myocardial infarction, one should ask what
relation exists between IgE and other main factors of
the atherothrombotic process, namely lipid disorders
and intravascular coagulation activation markers.
A significant increase of coagulation activation
markers in myocardial infarction has been noted by
many authors. TAT complex concentrations were
highest during the first 24 hours after infarction
[20, 21]. Szczeklik et al. [20] found significantly in-
creased levels of TAT complexes in the majority
(90%) of the group of 100 AMI patients. Maintained
high concentrations of TAT complexes predicted
a worse prognosis. They were observed in patients
with reinfarction and heart failure. The authors own
study revealed significantly increased levels of TAT
complexes in 70% of the patients with myocardial
infarction. The highest values were observed at
baseline; lower but not significantly: on the 7th, 14th
and 40th days. The analysis of the results of the pro-
spective Nortwick Park Heart Study (NPHS) in
patients without initially diagnosed IHD allowed the
authors to conclude that the majority of cardiac
deaths concerned people with extreme AT III ac-
tivity (high or low) diagnosed previously [22]. The
conclusions emerging from the results of both
PLAT and the Rotterdam studies imply that pa-
tients with active atheromatic process have in-
creased levels of ATIII activity, which is a result of
the activation of defence mechanisms against pro-
thrombotic influences and clearly indicates that the
increased risk of cardiovascular diseases is associ-
ated with increased ATIII activity [23, 24]. In the
literature, the majority of authors stress the in-
creased concentration of t-PA:Ag as a myocardial
infarction factor. The high concentration of t-PA, as
a risk of myocardial infarction, is often accompanied
with high PAI-1 activity. It has been suggested that
the high PAI-1 activity is responsible for the im-
paired fibrinolytic plasma activity and may play an
important role in the clot formation in coronary ar-
teries [25, 26]. Increased PAP and DD concentra-
tions turned out to be independent MI risk factors.
Activation of fibrinolysis, as secondary to coagula-
tion activation, brings about increased concentra-
tions of the markers, which, even in the early stage
of observations, prognosticate coronary incidents,
particularly myocardial infarction and sudden
Table 5. Correlation of log(IgE) with lipid and
hemostatic parameters in myocardial infarction
patients with baseline IgE levels above 200 kU/l.
Covariables Correlation Significance
coefficient (r)  level (p)
Lipid parameters
CH [mg/dl] 0.62 0.05
HDL [mg/ml] 0.07 NS
LDL [mg/dl] 0.67 0.02
TG [mg/dl] 0.10 NS
Lp(a) [mg/dl] 0.47 NS
Thrombin generation markers
TAT [mg/l] 0.81 0.001
Log(TAT) [mg/l] 0.80 0.002
ATIII [%] 0.59 0.05
Fibrinolytic system markers
t-PA:Ag [ng/ml] 0.07 NS
PAI-1:Ag [ng/ml] 0.50 NS
PAP [ng/ml] 0.05 NS
D-dimers [ng/ml] 0.42 NS
Endothelium damage markers
v. Willebrand [%] 0.30 NS
t-PA:Ag [ng/ml] 0.07 NS
Table 6. Correlation between increments of IgE
values and increments of coagulation activation
markers in patients in the course of myocardial
infarction.
Parameters Day 17 Day 114 Day 140
(n = 54) (n = 52) (n = 42)
r p r p r p
TAT [mg/l] 0.38 0.02 0.32 0.05 0.44 0.02
ATIII [%] 0.18 NS 0.19 NS 0.14 NS
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cardiac death [27]. In patients with atherosclerosis
and IHD, the von Willebrand factor was also in-
creased. The von Willebrand factor indicates the
increased risk of MI, reinfarction and death [25].
In the evaluated group of patients with acute
myocardial infarction, as compared to the control
group, we found significant differences in concentra-
tions of thrombin generation markers, fibrinolytic
system and endothelium damage markers.
Bearing in mind literature reports and the au-
thors own research on increased IgE concentra-
tions in patients with IHD, especially in myocardial
infarction, as well as increased lipid parameters and
markers enabling detection of thrombotic risk in
those patients, it seemed necessary to evaluate
correlations of IgE with both lipid parameters and
with representative hemostatic markers. The eval-
uation of relations between immunoglobulin E with
coagulation and fibrinolysis markers may have cast
light on the IgE role as a possible co-participant of
IHD pathogenesis.
In the available literature we have not come
across any reports on IgE relation with markers of
hemostatic disorders in humans, apart from the
observations by Szczeklik et al. [8], who were the
first to draw attention to the delay in thrombin gen-
eration in MI patients and the high serum IgE con-
centration (geometrical mean > 70 kU/L). It
seemed indispensable to broaden the evaluation of
the possible relation of IgE to not only include
thrombin generation markers, but also other markers
of activation of coagulation cascade, markers of plas-
ma fibrinolysis and markers of endothelial damage.
The correlation of IgE with the above men-
tioned factors in all patients with coronary artery
disease included in the study, regardless of the level
of IgE concentration, did not reveal a statistical sig-
nificance, apart from the negative and statistically
significant correlation with PAP in MI patients
(p < 0.05). The correlation of IgE concentration
with log(TAT) was close to statistical significance.
Nevertheless, in patients with myocardial infarction
but with IgE concentration above 100 kU/L and
above 150 kU/L and 200 kU/L, we found statistically
significant positive correlations of log(IgE) with lip-
id parameters and parameters of thrombinogenesis.
The possible relation of dyslipidemia and im-
mune deficiencies with acute coronary syndromes
was presented in the five-year prospective obser-
vation of men with lipid disorders within the Hel-
sinki Heart Study, which attempted to evaluate the
relation between the serum levels of immunoglob-
ulins E, A and G, and the size of coronary incident
risk (fatal or non-fatal myocardial infarction, or sud-
den cardiac death). The results of the study showed
that the risk of coronary heart disease remained
significantly correlated with IgE concentration, re-
gardless of other risk factors, such as: age, smok-
ing and high blood pressure. The risk in patients
with IgE concentration in the highest quartile was
as much as 2.8 times higher compared to patients
whose serum concentration of immunoglobulin
were in the lowest quartile.
Having found a close relation between increased
concentrations of immunoglobulins and increased
concentration of lipids in plasma, particularly choles-
terol in patients with myocardial infarction, the au-
thors came to the conclusion that immune mecha-
nisms participate in the development of atherothrom-
botic process, the result of which is myocardial
infarction [28]. In our study, similarly to the above
mentioned studies, neither triglycerides nor HDL
cholesterol displayed so close a relation with in-
creased IgE concentrations as the level of total cho-
lesterol and LDL cholesterol.  What catches the at-
tention, however, is the relation between IgE and
lp(a), that combines the influence of lipid and throm-
botic factors on atherosclerosis [29, 30].
A positive correlation between higher IgE val-
ues and TAT complexes and ATIII, as well as with
total cholesterol, LDL and Lp(a) found in our study,
may show the relation of the immunoglobulin with
factors playing an important role in the athero-
thrombotic process. The relation between IgE con-
centrations and fibrinolysis markers in our study
was not very convincing. Even though we observed
a negative correlation of IgE with PAP complexes
in all the MI patients, it was not significant at higher
IgE concentrations.
It is quite difficult to evaluate the direct corre-
lation between IgE concentration and the studied
markers of intravascular coagulation and fibrinoly-
sis activation in patients in the first hours after in-
farction. This results from considerable and multi-
directional changes in hemostasis entailed by the
infarction itself as well as by the administered treat-
ment. Our study revealed that on the 7th, 14th and
40th days after the infarction a positive significant
correlation was maintained between IgE concentra-
tions and the increase in TAT concentrations, which
confirmed the relation between the two parameters
on the first day of the infarction, as proved before
(p < 0.02, 0.05 and 0.02 respectively).
In the existing publications, we have not come
across any other similar observations concerning
the relation between IgE dynamics and those sen-
sitive thrombinogenesis markers in acute myocar-
dial infarction.
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Conclusions
1. In patients with acute myocardial infarction,
a significant increase in plasma levels of markers
of thrombinogenesis and fibrinolysis activation
is observed.
2. The positive correlation between IgE concen-
trations above 100 kU/L with lipid parameters
and intravascular coagulation activation mark-
ers, with significance increasing with higher IgE
levels as well as positive correlation between
increments of serum IgE levels and TAT com-
plexes, may serve as evidence of the significant
relation between this immunoglobulin and fac-
tors playing a vital role in the atherothrombotic
process in myocardial infarction patients.
3. The increased concentration of IgE may be re-
garded as a marker of atherosclerosis and
a witness of hemostatic risk factors of ischemic
heart disease.
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